Skip to main content

Declaratory judgment requested on Adamas Pharmaceuticals

Osmotica Pharmaceuticals and Vertical Pharmaceuticals requested a declaratory judgment that Osmotica's OSMOLEX ER does not infringe on certain of Adamas Pharmaceuticals Inc.'s (Nasdaq: ADMS) patents. Shares of Adamas plummeted $7.38 to close at $26.39.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.